Search Results

How Oregon's Prescription Drug Affordability Board affects patient access: statute, board actions, public Oregon PDAB Back to PDAB Policy Center Information, updates, and engagement opportunities related to PDAB March 2026 Publication date: 3/1/26 Comment addressing Oregon PDAB's March 2026 meeting on orphan View PDF CANN Public Comment: Oregon PDAB January 2026 Publication date: 1/1/26 Comment addressing Oregon View PDF CANN Public Comment: Oregon PDAB Drug Reviews Publication date: 8/17/25 Comment on Oregon PDAB's

Patient-centered tracking of 340B policy in Oregon: active bills, committee assignments, fact sheets, Oregon 340B Watch Stay informed on state-level actions, proposed legislation, and advocacy efforts shaping View PDF CANN Public Comment: Oregon HB 2385 — 340B Program Publication Date: 5/8/25 CANN opposes HB View PDF CANN Public Comment: Oregon HB 3409 — 340B Program Publication Date: 4/22/25 CANN opposes HB View PDF CANN Public Comment: Oregon HB 2385 — 340B Program Publication Date: 3/10/25 CANN opposes HB

Colorado Maryland New Jersey Connecticut Massachusetts Ohio Illinois Michigan Oregon Iowa Minnesota Vermont source spreadsheet behind CANN's ADA analysis — every PDAB-eligible drug across Colorado, Maryland, Oregon Published: July 23, 2024 Original data analysis of every PDAB-eligible drug in Colorado, Maryland, Oregon

specialty medications, and harm 340B providers via upper payment limits. 03/23/2026 CANN Public Comment: Oregon PDAB March 2026 Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and medications, and harm 340B providers via upper payment limits. 03/23/2026 Public Comment CANN Public Comment: Oregon PDAB March 2026 Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and

Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon